AR064425A1 - Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales - Google Patents

Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales

Info

Publication number
AR064425A1
AR064425A1 ARP070105702A AR064425A1 AR 064425 A1 AR064425 A1 AR 064425A1 AR P070105702 A ARP070105702 A AR P070105702A AR 064425 A1 AR064425 A1 AR 064425A1
Authority
AR
Argentina
Prior art keywords
saturated
liquid preparation
mixtures
group
penetration enhancer
Prior art date
Application number
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR064425A1 publication Critical patent/AR064425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparaciones transdérmicas que combinan un fármaco anti-inflamatorio no esteroide (NSAID) tales como flunixina. También métodos para utilizar y administrar dicha preparacion en el tratamiento de afecciones inflamatorias en bovinos, que incluyen la enfermedad respiratoria bovina. Reivindicacion 1: Una preparacion líquida transdérmica que comprende: a) un primer y un segundo mejorador de la penetracion dérmica; b) un solvente primario aprotico; y c) una cantidad terapéuticamente efectiva de flunixina o una sal farmacéuticamente aceptable de la misma. Reivindicacion 7: La preparacion líquida transdérmica de la reivindicacion 1, en donde el primer mejorador de la penetracion dérmica está seleccionado del grupo de terpenoides integrado por mentol, alcanfor, d-limoneno, nerolidol, o 1-8 Cineol y las mezclas de los mismos. Reivindicacion 8: La preparacion líquida transdérmica de la reivindicacion 1, en donde el segundo mejorador de la penetracion dérmica está seleccionado del grupo integrado por terpenoides, ésteres o diésteres de ácidos grasos saturados o no saturados de propilen glicol y glicerol, ácidos grasos saturados o no saturados, alcoholes grasos saturados o no saturados, y las mezclas de los mismos. Reivindicacion 11: La preparacion líquida transdérmica de la reivindicacion 1, en donde el solvente primario aprotico está seleccionado del grupo integrado por un solvente de pirrolidona, N,N-dimetilacetamida, N,N-dimetilformamida, DMSO, acetona, glicerol formal lactato de etilo, ésteres de glicol, y/o las mezclas de los mismos.
ARP070105702 2006-12-20 2007-12-18 Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales AR064425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87090706P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
AR064425A1 true AR064425A1 (es) 2009-04-01

Family

ID=39262615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105702 AR064425A1 (es) 2006-12-20 2007-12-18 Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales

Country Status (19)

Country Link
US (1) US9006272B2 (es)
EP (1) EP2120860B1 (es)
JP (1) JP5377326B2 (es)
KR (1) KR20090091328A (es)
CN (2) CN103690471B (es)
AR (1) AR064425A1 (es)
AU (1) AU2007339312B2 (es)
BR (1) BRPI0720500B1 (es)
CA (1) CA2672964C (es)
CL (1) CL2007003711A1 (es)
CO (1) CO6190598A2 (es)
ES (1) ES2714550T3 (es)
MX (1) MX2009006893A (es)
NZ (1) NZ598554A (es)
PE (1) PE20081406A1 (es)
RU (1) RU2466715C2 (es)
TW (1) TWI350182B (es)
WO (1) WO2008082507A2 (es)
ZA (1) ZA200904329B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050889A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
WO2011112875A2 (en) 2010-03-10 2011-09-15 Nuvo Research Inc. Foamable formulation
WO2012022837A1 (en) * 2010-08-16 2012-02-23 Helsingin Yliopisto Transdermal compositions
CN103179970B (zh) * 2010-09-30 2015-11-25 富山化学工业株式会社 透皮吸收制剂
CN114903848A (zh) * 2013-02-27 2022-08-16 阿根塔创新有限公司 透皮制剂
CN105769827B (zh) * 2016-03-09 2018-07-17 金陵科技学院 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法
KR20200065711A (ko) 2018-11-30 2020-06-09 한원경 동물 피부질환 개선용 조성물
AU2020315758A1 (en) 2019-07-16 2022-02-10 Donaghys Limited Transdermal solvent system and methods of use
WO2021045870A1 (en) * 2019-09-06 2021-03-11 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
WO2022112277A1 (en) * 2020-11-25 2022-06-02 Intervet International B.V. Method of treatment of pain through buccal administration of flunixin
WO2022238965A1 (en) * 2021-05-12 2022-11-17 Argenta Innovation Limited Veterinary transdermal formulation
CN114404360B (zh) * 2021-12-16 2023-03-28 江西益昕葆生物科技有限公司 一种氟尼辛葡甲胺注射液的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225316A (ja) * 1986-10-21 1988-09-20 Nitto Electric Ind Co Ltd 外皮投与用組成物
JPH11222443A (ja) * 1997-11-11 1999-08-17 Saitama Daiichi Seiyaku Kk 経皮吸収促進組成物および経皮吸収製剤
AU1780101A (en) * 1999-11-19 2001-05-30 Xel Herbaceuticals Transdermal delivery system for alkaloids of aconitum species
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CA2530407A1 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
AU2004258745A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
BRPI0513401A (pt) * 2004-07-19 2008-05-06 Warner Lambert Co formulação para estimular crescimento de cabelo
JP2008513388A (ja) * 2004-09-16 2008-05-01 バイエル・ヘルスケア・アクチェンゲゼルシャフト 動物の皮膚病を処置するための皮膚投与可能な製剤
KR20080071185A (ko) 2005-11-21 2008-08-01 쉐링-프라우 리미티드 부프레노르핀을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
US20080153885A1 (en) 2008-06-26
RU2466715C2 (ru) 2012-11-20
BRPI0720500B1 (pt) 2019-01-02
JP5377326B2 (ja) 2013-12-25
BRPI0720500A8 (pt) 2015-12-29
AU2007339312A1 (en) 2008-07-10
WO2008082507A3 (en) 2009-03-19
CN103690471A (zh) 2014-04-02
NZ598554A (en) 2013-08-30
CN103690471B (zh) 2015-11-18
ZA200904329B (en) 2010-05-26
PE20081406A1 (es) 2008-10-17
WO2008082507A2 (en) 2008-07-10
AU2007339312B2 (en) 2013-06-06
ES2714550T3 (es) 2019-05-29
CN101588789A (zh) 2009-11-25
TWI350182B (en) 2011-10-11
BRPI0720500A2 (pt) 2014-02-04
CL2007003711A1 (es) 2008-07-25
CN101588789B (zh) 2013-12-11
US9006272B2 (en) 2015-04-14
CA2672964A1 (en) 2008-07-10
EP2120860A2 (en) 2009-11-25
KR20090091328A (ko) 2009-08-27
TW200833367A (en) 2008-08-16
CO6190598A2 (es) 2010-08-19
MX2009006893A (es) 2009-07-03
JP2010513500A (ja) 2010-04-30
EP2120860B1 (en) 2019-01-23
CA2672964C (en) 2018-04-03
RU2009127500A (ru) 2011-01-27

Similar Documents

Publication Publication Date Title
AR064425A1 (es) Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales
AR072223A1 (es) Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en el ganado vacuno
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AU2006233502B2 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
JP6794420B2 (ja) 外用医薬組成物
JP2010513500A5 (es)
AR025434A1 (es) Formulacion farmaceutica con contenido de derivados de benzamida, con solubilidad y absorcion oral mejoradas
RU2008114352A (ru) Композиции для местного применения
Li et al. Development of patch and spray formulations for enhancing topical delivery of sinomenine hydrochloride
CN101530401A (zh) 一种用于治疗急慢性炎性疼痛的复方透皮贴片
AR048342A1 (es) FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)
RU2017109903A (ru) Композиции диклофенака натрия для местного применения
CO2021011652A2 (es) Ésteres de ácido graso como agentes anti-malassezia
JP2022551696A (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
RU2016137349A (ru) Успокоительный феромон для кошек
UY29150A1 (es) Capsulas de lercanidipino
AR110468A1 (es) Formulaciones de buprenorfina de liberación sostenida y método de tratamiento
RS50693B (sr) Stabilni farmaceutski gel diklofenak natrijuma
RU2005132004A (ru) Стабилизированные композиции для местного применения, содержащие кетопрофен
AU2013200466A1 (en) Compositions For The Treatment Of Actinic Keratosis
KR100880056B1 (ko) 화상 치료용 제약 조성물
WO2011015692A2 (es) Uso del ácido maslínico para el tratamiento de dolores de naturaleza nociceptiva, inflamatoria y neurogénica
KR100552651B1 (ko) 비스테로이드성 소염진통제 함유 플라스터
WO2015016695A1 (es) Novedoso sistema farmacéutico de entrega bifásica para el tratamiento del dolor y la inflamación
AR086447A1 (es) Composicion farmaceutica que comprende ketoprofeno

Legal Events

Date Code Title Description
FC Refusal